Combined modalities in the treatment of head and neck cancers

J. Aisner, D. Hiponia, B. Conley, M. Jacobs, W. Gray, Chandra Belani

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The higher the T and N stages at diagnosis of head and neck cancer, the lower the proportion of patients who achieve complete, durable local control and the lower the survival. These cancers and their treatments often produce considerable anatomic distortion, affecting function, nutritional status, and appearance. New treatment approaches for locally and regionally advanced head and neck cancers are thus needed to improve survival, quality of life, or both. Combined-modality approaches show promise. Induction chemotherapy and subsequent radiotherapy produce results equivalent to aggressive surgery but allow for better organ function and speech. Induction chemotherapy and radiotherapy are superior to radiotherapy alone. Concurrent chemotherapy and radiotherapy may produce additive or synergistic interactions but increase toxicities. Some studies suggest that concurrent chemotherapy and radiotherapy significantly improves survival over radiotherapy alone in regionally advanced disease. Drug selection criteria have included enhancement of radiation cytotoxicity, effect on cellular kinetics, and, possibly, single-agent antitumor activity. The platinum compounds are of interest, especially in combination with other chemotherapy agents, like 5- fluorouracil and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ). Concurrent carboplatin and radiotherapy produced a 77-week duration of survival in responders in a University of Maryland Cancer Center study. A study of concurrent carboplatin/bleomycin/radiotherapy had to be halted because of severe bleomycin-induced mucositis. The results in this small group suggest that attenuating mucositis would be desirable. In a subsequent trial, paclitaxel, which shows considerable activity against head and neck cancers, was substituted for bleomycin. Data from the seven patients accrued thus far are too immature to define response. The study continues to accrue patients.

Original languageEnglish (US)
Pages (from-to)28-34
Number of pages7
JournalSeminars in oncology
Volume22
Issue number3 SUPPL. 6
StatePublished - Jul 10 1995

Fingerprint

Head and Neck Neoplasms
Radiotherapy
Bleomycin
Paclitaxel
Mucositis
Induction Chemotherapy
Survival
Carboplatin
Therapeutics
Drug Therapy
Cohort Studies
Platinum Compounds
Radiation Effects
Nutritional Status
Fluorouracil
Antineoplastic Agents
Patient Selection
Neoplasms
Quality of Life
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Aisner, J., Hiponia, D., Conley, B., Jacobs, M., Gray, W., & Belani, C. (1995). Combined modalities in the treatment of head and neck cancers. Seminars in oncology, 22(3 SUPPL. 6), 28-34.
Aisner, J. ; Hiponia, D. ; Conley, B. ; Jacobs, M. ; Gray, W. ; Belani, Chandra. / Combined modalities in the treatment of head and neck cancers. In: Seminars in oncology. 1995 ; Vol. 22, No. 3 SUPPL. 6. pp. 28-34.
@article{d38348c66edf44ecba86f6ad94aaf21c,
title = "Combined modalities in the treatment of head and neck cancers",
abstract = "The higher the T and N stages at diagnosis of head and neck cancer, the lower the proportion of patients who achieve complete, durable local control and the lower the survival. These cancers and their treatments often produce considerable anatomic distortion, affecting function, nutritional status, and appearance. New treatment approaches for locally and regionally advanced head and neck cancers are thus needed to improve survival, quality of life, or both. Combined-modality approaches show promise. Induction chemotherapy and subsequent radiotherapy produce results equivalent to aggressive surgery but allow for better organ function and speech. Induction chemotherapy and radiotherapy are superior to radiotherapy alone. Concurrent chemotherapy and radiotherapy may produce additive or synergistic interactions but increase toxicities. Some studies suggest that concurrent chemotherapy and radiotherapy significantly improves survival over radiotherapy alone in regionally advanced disease. Drug selection criteria have included enhancement of radiation cytotoxicity, effect on cellular kinetics, and, possibly, single-agent antitumor activity. The platinum compounds are of interest, especially in combination with other chemotherapy agents, like 5- fluorouracil and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ). Concurrent carboplatin and radiotherapy produced a 77-week duration of survival in responders in a University of Maryland Cancer Center study. A study of concurrent carboplatin/bleomycin/radiotherapy had to be halted because of severe bleomycin-induced mucositis. The results in this small group suggest that attenuating mucositis would be desirable. In a subsequent trial, paclitaxel, which shows considerable activity against head and neck cancers, was substituted for bleomycin. Data from the seven patients accrued thus far are too immature to define response. The study continues to accrue patients.",
author = "J. Aisner and D. Hiponia and B. Conley and M. Jacobs and W. Gray and Chandra Belani",
year = "1995",
month = "7",
day = "10",
language = "English (US)",
volume = "22",
pages = "28--34",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "3 SUPPL. 6",

}

Aisner, J, Hiponia, D, Conley, B, Jacobs, M, Gray, W & Belani, C 1995, 'Combined modalities in the treatment of head and neck cancers', Seminars in oncology, vol. 22, no. 3 SUPPL. 6, pp. 28-34.

Combined modalities in the treatment of head and neck cancers. / Aisner, J.; Hiponia, D.; Conley, B.; Jacobs, M.; Gray, W.; Belani, Chandra.

In: Seminars in oncology, Vol. 22, No. 3 SUPPL. 6, 10.07.1995, p. 28-34.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Combined modalities in the treatment of head and neck cancers

AU - Aisner, J.

AU - Hiponia, D.

AU - Conley, B.

AU - Jacobs, M.

AU - Gray, W.

AU - Belani, Chandra

PY - 1995/7/10

Y1 - 1995/7/10

N2 - The higher the T and N stages at diagnosis of head and neck cancer, the lower the proportion of patients who achieve complete, durable local control and the lower the survival. These cancers and their treatments often produce considerable anatomic distortion, affecting function, nutritional status, and appearance. New treatment approaches for locally and regionally advanced head and neck cancers are thus needed to improve survival, quality of life, or both. Combined-modality approaches show promise. Induction chemotherapy and subsequent radiotherapy produce results equivalent to aggressive surgery but allow for better organ function and speech. Induction chemotherapy and radiotherapy are superior to radiotherapy alone. Concurrent chemotherapy and radiotherapy may produce additive or synergistic interactions but increase toxicities. Some studies suggest that concurrent chemotherapy and radiotherapy significantly improves survival over radiotherapy alone in regionally advanced disease. Drug selection criteria have included enhancement of radiation cytotoxicity, effect on cellular kinetics, and, possibly, single-agent antitumor activity. The platinum compounds are of interest, especially in combination with other chemotherapy agents, like 5- fluorouracil and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ). Concurrent carboplatin and radiotherapy produced a 77-week duration of survival in responders in a University of Maryland Cancer Center study. A study of concurrent carboplatin/bleomycin/radiotherapy had to be halted because of severe bleomycin-induced mucositis. The results in this small group suggest that attenuating mucositis would be desirable. In a subsequent trial, paclitaxel, which shows considerable activity against head and neck cancers, was substituted for bleomycin. Data from the seven patients accrued thus far are too immature to define response. The study continues to accrue patients.

AB - The higher the T and N stages at diagnosis of head and neck cancer, the lower the proportion of patients who achieve complete, durable local control and the lower the survival. These cancers and their treatments often produce considerable anatomic distortion, affecting function, nutritional status, and appearance. New treatment approaches for locally and regionally advanced head and neck cancers are thus needed to improve survival, quality of life, or both. Combined-modality approaches show promise. Induction chemotherapy and subsequent radiotherapy produce results equivalent to aggressive surgery but allow for better organ function and speech. Induction chemotherapy and radiotherapy are superior to radiotherapy alone. Concurrent chemotherapy and radiotherapy may produce additive or synergistic interactions but increase toxicities. Some studies suggest that concurrent chemotherapy and radiotherapy significantly improves survival over radiotherapy alone in regionally advanced disease. Drug selection criteria have included enhancement of radiation cytotoxicity, effect on cellular kinetics, and, possibly, single-agent antitumor activity. The platinum compounds are of interest, especially in combination with other chemotherapy agents, like 5- fluorouracil and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ). Concurrent carboplatin and radiotherapy produced a 77-week duration of survival in responders in a University of Maryland Cancer Center study. A study of concurrent carboplatin/bleomycin/radiotherapy had to be halted because of severe bleomycin-induced mucositis. The results in this small group suggest that attenuating mucositis would be desirable. In a subsequent trial, paclitaxel, which shows considerable activity against head and neck cancers, was substituted for bleomycin. Data from the seven patients accrued thus far are too immature to define response. The study continues to accrue patients.

UR - http://www.scopus.com/inward/record.url?scp=0029065868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029065868&partnerID=8YFLogxK

M3 - Article

C2 - 7541154

AN - SCOPUS:0029065868

VL - 22

SP - 28

EP - 34

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 3 SUPPL. 6

ER -

Aisner J, Hiponia D, Conley B, Jacobs M, Gray W, Belani C. Combined modalities in the treatment of head and neck cancers. Seminars in oncology. 1995 Jul 10;22(3 SUPPL. 6):28-34.